🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2025-521707-48-00
Completed Phase I

AMG 410 Alone and in Combination with other agents in Participants with KRAS Altered Advanced or Metastatic Solid Tumors

2025-521707-48-00 · tracked via the Priya Life Science EU tracker
Sponsor
Amgen Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
28/10/2025
Enrollment target
135
Sites
France, Netherlands, Germany, Denmark, Spain, Italy, Belgium

Condition studied

KRAS Altered Advanced or Metastatic Solid Tumors

Eligibility

Age group
65+ years, 18-64 years
Sex
Female, Male
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2025-521707-48-00 on CTIS ↗ ← All trials in the EU